JP7114567B2 - 生体分子を含む高濃縮液体製剤の調製のためのプロセス - Google Patents

生体分子を含む高濃縮液体製剤の調製のためのプロセス Download PDF

Info

Publication number
JP7114567B2
JP7114567B2 JP2019508243A JP2019508243A JP7114567B2 JP 7114567 B2 JP7114567 B2 JP 7114567B2 JP 2019508243 A JP2019508243 A JP 2019508243A JP 2019508243 A JP2019508243 A JP 2019508243A JP 7114567 B2 JP7114567 B2 JP 7114567B2
Authority
JP
Japan
Prior art keywords
salts
acid
protein
liquid medium
biomolecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019508243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535641A (ja
Inventor
ガリデル，パトリック
バーレンブルク，スヴェン
シュルツ－ファーデムレヒト，トルシュテン
アイペルレ，アンドレア
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2019535641A publication Critical patent/JP2019535641A/ja
Priority to JP2022092326A priority Critical patent/JP2022120016A/ja
Application granted granted Critical
Publication of JP7114567B2 publication Critical patent/JP7114567B2/ja
Priority to JP2024060940A priority patent/JP2024081786A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019508243A 2016-08-17 2017-08-11 生体分子を含む高濃縮液体製剤の調製のためのプロセス Active JP7114567B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022092326A JP2022120016A (ja) 2016-08-17 2022-06-07 生体分子を含む高濃縮液体製剤の調製のためのプロセス
JP2024060940A JP2024081786A (ja) 2016-08-17 2024-04-04 生体分子を含む高濃縮液体製剤の調製のためのプロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16184502.9 2016-08-17
EP16184502 2016-08-17
PCT/EP2017/070423 WO2018033482A1 (en) 2016-08-17 2017-08-11 Process for the preparation of highly concentrated liquid formulations containing biomolecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022092326A Division JP2022120016A (ja) 2016-08-17 2022-06-07 生体分子を含む高濃縮液体製剤の調製のためのプロセス

Publications (2)

Publication Number Publication Date
JP2019535641A JP2019535641A (ja) 2019-12-12
JP7114567B2 true JP7114567B2 (ja) 2022-08-08

Family

ID=56740111

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019508243A Active JP7114567B2 (ja) 2016-08-17 2017-08-11 生体分子を含む高濃縮液体製剤の調製のためのプロセス
JP2022092326A Pending JP2022120016A (ja) 2016-08-17 2022-06-07 生体分子を含む高濃縮液体製剤の調製のためのプロセス
JP2024060940A Pending JP2024081786A (ja) 2016-08-17 2024-04-04 生体分子を含む高濃縮液体製剤の調製のためのプロセス

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022092326A Pending JP2022120016A (ja) 2016-08-17 2022-06-07 生体分子を含む高濃縮液体製剤の調製のためのプロセス
JP2024060940A Pending JP2024081786A (ja) 2016-08-17 2024-04-04 生体分子を含む高濃縮液体製剤の調製のためのプロセス

Country Status (9)

Country Link
US (1) US11572385B2 (de)
EP (1) EP3500588A1 (de)
JP (3) JP7114567B2 (de)
KR (1) KR102457855B1 (de)
CN (2) CN118085011A (de)
AU (2) AU2017313268B2 (de)
CA (1) CA3031860A1 (de)
SG (1) SG11201901081XA (de)
WO (1) WO2018033482A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7162072B2 (ja) * 2018-03-26 2022-10-27 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 免疫原性組成物を製造する方法
AU2019250882A1 (en) * 2018-04-12 2020-11-05 Amgen Inc. Methods for making stable protein compositions
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
CN111096456A (zh) * 2020-02-14 2020-05-05 江西师范大学 一种荷叶中抑制晚期糖基化产物形成活性组分的制备方法
CA3229424A1 (en) 2021-09-02 2023-03-09 Boehringer Ingelheim International Gmbh Method of determining a future color value or corresponding property and arrangement therefor
WO2024008256A1 (en) * 2022-07-05 2024-01-11 Lihme Protein Solutions Improved apparatus for compound separation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031560A2 (en) 2004-09-09 2006-03-23 Genentech, Inc. Process for concentration of antibodies and therapeutic products thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199058A (en) * 1980-12-05 1985-04-30 Schreiber Foods Inc Producing cheese or a cheese base containing casein and whey proteins
SE500110C2 (sv) 1989-06-27 1994-04-18 Kabi Pharmacia Ab Sätt att rena ett protein från därtill bundna flervärda metalljoner
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5564414A (en) 1994-05-26 1996-10-15 Walker; William F. Pressurized and metered medication dose counter on removable sleeve
US6312755B1 (en) * 1999-07-16 2001-11-06 Ampc Whey treatment process for achieving high concentration of α-lactalbumin
US6693173B2 (en) 2000-12-26 2004-02-17 Alpha Therapeutic Corporation Method to remove citrate and aluminum from proteins
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US6712963B2 (en) * 2002-06-14 2004-03-30 Scilog, Llc Single-use manifold for automated, aseptic transfer of solutions in bioprocessing applications
US7241874B2 (en) * 2002-06-26 2007-07-10 Zimmer Ortho Biologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
EP1386630B1 (de) 2002-07-31 2006-05-17 CHIESI FARMACEUTICI S.p.A. Pulverinhalator
EP1596667B1 (de) 2002-11-01 2009-01-21 Bayer HealthCare LLC Verfahren zur Konzentration von Proteinen
CA2554883C (en) 2004-01-30 2013-10-01 Zymenex A/S Production and purification of recombinant arylsulfatase a
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
BRPI0614852B1 (pt) 2005-08-24 2019-06-18 Boehringer Ingelheim International Gmbh Pulverizador
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
DK2007506T3 (da) * 2006-03-31 2014-06-16 Danisco Us Inc Tangentialstrømningsfiltreringsapparater, -systemer og -fremgangsmådertil separering af forbindelser
ES2294976B1 (es) 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ602498A (en) * 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
US10080853B2 (en) 2011-05-23 2018-09-25 Boehringer Ingelheim International Gmbh Nebulizer
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2012161685A1 (en) 2011-05-23 2012-11-29 Boehringer Ingelheim International Gmbh Nebulizer
JP2013043865A (ja) * 2011-08-25 2013-03-04 Osaka Prefecture Univ 血中脂質降下剤及び高分子アディポネクチン産生促進剤
GB201115874D0 (en) 2011-09-14 2011-10-26 Astrazeneca Ab Inhaler
GB201122430D0 (en) 2011-12-23 2012-02-08 Xstalbio Ltd Reconstitution method for high concentration dry protein formulation
CN104755489B (zh) * 2012-10-30 2019-01-15 弗·哈夫曼-拉罗切有限公司 使用双级切线流超滤纯化多肽

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031560A2 (en) 2004-09-09 2006-03-23 Genentech, Inc. Process for concentration of antibodies and therapeutic products thereof

Also Published As

Publication number Publication date
CN118085011A (zh) 2024-05-28
AU2017313268A1 (en) 2019-02-07
CN110198952B9 (zh) 2024-05-28
US11572385B2 (en) 2023-02-07
CA3031860A1 (en) 2018-02-22
CN110198952B (zh) 2024-03-01
JP2024081786A (ja) 2024-06-18
JP2022120016A (ja) 2022-08-17
AU2017313268B2 (en) 2024-01-18
KR102457855B1 (ko) 2022-10-25
CN110198952A (zh) 2019-09-03
KR20190038921A (ko) 2019-04-09
JP2019535641A (ja) 2019-12-12
WO2018033482A1 (en) 2018-02-22
SG11201901081XA (en) 2019-03-28
US20190309016A1 (en) 2019-10-10
EP3500588A1 (de) 2019-06-26
AU2024202299A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
JP7114567B2 (ja) 生体分子を含む高濃縮液体製剤の調製のためのプロセス
AU2014265624B2 (en) Purification of recombinantly produced polypeptides
Hung et al. High concentration tangential flow ultrafiltration of stable monoclonal antibody solutions with low viscosities
IL258311A (en) A method for preparing a therapeutic protein formulation and an antibody formulation produced by the method
US20110236391A1 (en) Method for obtaining an excipient-free antibody solution
EP3060578A1 (de) Antikörperreinigung
JP2021535739A (ja) 下流精製でのラマン分光法の使用
Sviben et al. Investigation of the thermal shift assay and its power to predict protein and virus stabilizing conditions
WO2015140751A1 (en) Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
EP2483304B1 (de) Vorfiltrationseinstellung von gelösten pufferstoffen zur herstellung einer hochkonzentrierten immunglobulinzubereitung
JP7425041B2 (ja) 抗体医薬製剤を作製する方法
US20230182041A1 (en) Purification of antibodies
Saab Investigation the Plugging Behavior of Virus filters
JP2011504513A (ja) 免疫グロブリン凝集物
TW202140511A (zh) 減少來自重組蛋白生產過程中的雜質之方法
Bhiman Optimisation of ultrafiltration for human serum albumin at NBI

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210330

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210330

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210413

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210514

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210518

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210625

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210629

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211124

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220118

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220208

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220607

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220621

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220719

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220719

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220727

R150 Certificate of patent or registration of utility model

Ref document number: 7114567

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150